Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk A/S (NVO) kicked off 2026 with a major milestone: the U.S. launch of the Wegovy weight-loss pill. This marks the first oral GLP-1 therapy, which was approved by the Food and Drug Administration (FDA) in late December. And this wasn’t just another product rollout. It signaled a strategic shift in the way obesity treatment is delivered.

Where injectable GLP-1 drugs require in-office or self-administered shots, a daily pill dramatically lowers the barrier to treatment for millions of patients who prefer a familiar, convenient option. 

Fundamentals

See More
  • Market Capitalization, $K 270,936,192
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 19,514 M
  • EBITDA $ 22,285 M
  • 60-Month Beta 0.66
  • Price/Sales 5.49
  • Price/Cash Flow 15.98
  • Price/Book 10.46

Options Overview Details

View History
  • Implied Volatility 55.21% (+0.60%)
  • Historical Volatility 45.84%
  • IV Percentile 82%
  • IV Rank 59.13%
  • IV High 70.99% on 04/08/25
  • IV Low 32.36% on 02/11/25
  • Expected Move (DTE 2) 2.35 (3.94%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 169,260
  • Volume Avg (30-Day) 141,361
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 1,361,008
  • Open Int (30-Day) 1,501,833
  • Expected Range 57.20 to 61.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.91
  • Number of Estimates 3
  • High Estimate 0.92
  • Low Estimate 0.89
  • Prior Year 0.91
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.59 +24.57%
on 12/22/25
62.40 -4.99%
on 01/16/26
+11.19 (+23.28%)
since 12/19/25
3-Month
43.08 +37.62%
on 11/24/25
62.40 -4.99%
on 01/16/26
+4.51 (+8.22%)
since 10/21/25
52-Week
43.08 +37.62%
on 11/24/25
93.80 -36.80%
on 02/25/25
-21.74 (-26.84%)
since 01/21/25

Most Recent Stories

More News
The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

NVO : 59.32 (-2.24%)
JPM : 302.04 (-0.23%)
LLY : 1,078.52 (+3.58%)
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

VKTX : 33.39 (-0.39%)
AZN : 90.54 (+0.67%)
OZEM : 36.09 (+1.04%)
NVO : 59.32 (-2.24%)
LLY : 1,078.52 (+3.58%)
REGN : 749.33 (+2.12%)
AMGN : 343.60 (+3.81%)
PFE : 25.89 (+1.45%)
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

VTYX : 13.87 (-0.07%)
NVO : 59.32 (-2.24%)
LLY : 1,078.52 (+3.58%)
This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

CVS : 81.49 (+1.75%)
VHT : 294.37 (+1.73%)
NVO : 59.32 (-2.24%)
JNJ : 218.01 (-0.09%)
MRK : 111.11 (+1.52%)
HCA : 465.44 (+0.23%)
ABBV : 216.15 (+0.99%)
UNH : 347.75 (+2.75%)
ELV : 369.88 (+0.77%)
PFE : 25.89 (+1.45%)
TSLA : 431.44 (+2.91%)
LLY : 1,078.52 (+3.58%)
Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.

NVO : 59.32 (-2.24%)
LLY : 1,078.52 (+3.58%)
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

PLAINSBORO, N.J.and BAGSVÆRD, Denmark , Jan. 5, 2026 /PRNewswire/ -- Wegovy ® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine...

NVO : 59.32 (-2.24%)
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026

Novo Nordisk is down big in 2025, but hope is far from lost in 2026. The company's newly approved weight-loss pill could be the remedy that shares need.

NVO : 59.32 (-2.24%)
LLY : 1,078.52 (+3.58%)
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

Eli Lilly has been a huge winner in the last few months of 2025. New clinical data support its outlook in 2026, with large potential catalysts on the horizon.

NVO : 59.32 (-2.24%)
LLY : 1,078.52 (+3.58%)
As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

NVO : 59.32 (-2.24%)
$SPX : 6,875.62 (+1.16%)
LLY : 1,078.52 (+3.58%)
PFE : 25.89 (+1.45%)
Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

NVO : 59.32 (-2.24%)
JNJ : 218.01 (-0.09%)
LLY : 1,078.52 (+3.58%)
REGN : 749.33 (+2.12%)
PFE : 25.89 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 64.14
2nd Resistance Point 63.16
1st Resistance Point 61.92
Last Price 59.32
1st Support Level 59.70
2nd Support Level 58.72
3rd Support Level 57.48

See More

52-Week High 93.80
Fibonacci 61.8% 74.42
Fibonacci 50% 68.44
Fibonacci 38.2% 62.46
Last Price 59.32
52-Week Low 43.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar